Blueprint Medicines Trading Volume Drops 38.18% to $568 Million, Ranks 171st as Sanofi Acquisition Sparks Fairness Investigations

On June 10, 2025, Blueprint Medicines Corporation (BPMC) closed at a trading volume of $568 million, marking a 38.18% decrease from the previous day. This placed the company at the 171st position in terms of trading volume for the day.

Sanofi has announced its intention to acquire all outstanding shares of Blueprint Medicines Corporation for $129 per share in cash. This acquisition is part of Sanofi's strategy to expand its portfolio in rare immunological diseases and to add an early-stage pipeline in immunology. The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an early-stage immunology pipeline.

The proposed acquisition has sparked investigations into the fairness of the deal. Law firms such as Kahn Swick & Foti, LLC and Johnson Fistel, PLLP have launched investigations to determine whether the board members of Blueprint Medicines Corporation breached their fiduciary duties in the proposed sale. These investigations aim to ensure that the price and process of the acquisition are adequate and fair to shareholders.

Sanofi's acquisition of Blueprint Medicines is seen as a bullish signal for biotech M&A, indicating a positive outlook for mergers and acquisitions in the biotechnology sector. The deal is expected to strengthen Sanofi's position in the rare disease market and enhance its immunology portfolio.